SpinalCyte has announced today the issuance of Chinese Patent No. ZL 201110261353.3, “Method of Differentiating Human Dermal Fibroblasts into Chondrocyte-Like Cells Using Mechanical Strain.”
The technology described in the patent involves incorporating a three dimensional matrix to expose the fibroblasts to a mechanical strain using intermittent hydrostatic pressure and/or fluid shear stress. Other claims provide for exposing the cells to hypoxia, growth factors and ascorbic acid.
“This is a significant milestone for us and we are pleased the Chinese Patent Office has validated the uniqueness of our technology, which includes 10 US and foreign patents issued and directly owned by the company, along with 34 patents pending,” says Pete O’Heeron, chief executive officer for SpinalCyte. “We feel the future for spinal disc regeneration will be a cell based therapy solution and we continue to build our intellectual property to protect our leading position in this field.”